GlassScriptPhysician profile
Luis Alvarez
NPI 1477916708
$4,332.19
in general payments reported to CMS, 2019-2025
11 companies · $4,060 in 2025
The $4,060 reported for 2025 was more than what 97% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $272 · 2025: $4,060.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $2,943 · Food and Beverage: $1,390.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $2,942.50 |
| Food and Beverage | $1,389.69 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sobi, INC | $3,035.57 | 2025 | |
| Amgen INC. | $723.70 | 2024-2025 | Otezla, Enbrel, Tavneos |
| Astrazeneca Pharmaceuticals LP | $150.10 | 2025 | Saphnelo |
| Novartis Pharmaceuticals Corporation | $113.37 | 2025 | |
| Janssen Biotech, INC. | $80.98 | 2025 | Tremfya |
| Aurinia Pharma U.S., INC. | $53.08 | 2024 | Lupkynis |
| Boehringer Ingelheim Pharmaceuticals, INC. | $42.25 | 2025 | |
| Ani Pharmaceuticals, INC. | $39.39 | 2025 | Purified Cortrophin Gel |
| Glaxosmithkline, LLC. | $37.79 | 2025 | Benlysta |
| E.R. Squibb & Sons, L.L.C. | $37.61 | 2025 | Orencia |
| Alexion Pharmaceuticals, INC. | $18.35 | 2025 | Strensiq |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Luis Alvarez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.